Exelixis (EXEL) Tops Q4 EPS by 13c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall St mixed as Middle East tensions eclipse tech strength
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
Exelixis (EXEL) PT Raised to $33 at Needham & Company
February 13, 2019 10:52 AM ESTNeedham & Company analyst Chad Messer raised the price target on Exelixis (NASDAQ: EXEL) to $33.00 (from $30.00) while maintaining a Buy rating.
Messer commented, "Exelixis reported $176M in Cabo sales in 4Q:18, an 8% increase q/q. FY18 Cabo sales were $619M, a 44% increase... More
Exelixis (EXEL) PT Raised to $33 at Guggenheim Following 4Q
February 13, 2019 10:01 AM ESTGuggenheim analyst Michael Schmidt raised the price target on Exelixis (NASDAQ: EXEL) to $33.00 (from $31.00) while maintaining a Buy rating following the company's 4Q earnings report. EXEL reported 4Q18 revenue of $229M, 22% above Street consensus of $188M. Non-GAAP diluted EPS was 0.37, driven mostly by a... More
Exelixis (EXEL) PT Lowered to $31 at Oppenheimer
February 13, 2019 7:58 AM ESTOppenheimer analyst Silvan Tuerkcan lowered the price target on Exelixis (NASDAQ: EXEL) to $31.00 (from $40.00) while maintaining a Outperform rating.
The analyst commented, "EXEL reported 4Q $176.2M revenue beating $170.0M consensus driven by Cabometyx sales of $171.6M vs $166M consensus. Cabometyx sales grew... More
